900 related articles for article (PubMed ID: 12223530)
1. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
Virág L; Szabó C
Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
[TBL] [Abstract][Full Text] [Related]
2. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
Komjáti K; Besson VC; Szabó C
Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) polymerase inhibitors.
Southan GJ; Szabó C
Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
[TBL] [Abstract][Full Text] [Related]
4. Alternative mechanisms of inhibiting activity of poly (ADP-ribose) polymerase-1.
Sriram CS; Jangra A; Bezbaruah BK; V AK; Sykam S
Front Biosci (Schol Ed); 2016 Jan; 8(1):123-8. PubMed ID: 26709902
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
6. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Virág L
Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Horvath EM; Szabó C
Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
de la Lastra CA; Villegas I; Sánchez-Fidalgo S
Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications.
Sodhi RK; Singh N; Jaggi AS
Vascul Pharmacol; 2010; 53(3-4):77-87. PubMed ID: 20633699
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
11. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
Tentori L; Portarena I; Graziani G
Pharmacol Res; 2002 Feb; 45(2):73-85. PubMed ID: 11846617
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation.
Erdélyi K; Bakondi E; Gergely P; Szabó C; Virág L
Cell Mol Life Sci; 2005 Apr; 62(7-8):751-9. PubMed ID: 15868400
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection.
Skaper SD
Ann N Y Acad Sci; 2003 May; 993():217-28; discussion 287-8. PubMed ID: 12853316
[TBL] [Abstract][Full Text] [Related]
14. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress.
Decker P; Muller S
Curr Pharm Biotechnol; 2002 Sep; 3(3):275-83. PubMed ID: 12164482
[TBL] [Abstract][Full Text] [Related]
15. Natural inhibitors of poly(ADP-ribose) polymerase-1.
Banasik M; Stedeford T; Strosznajder RP
Mol Neurobiol; 2012 Aug; 46(1):55-63. PubMed ID: 22476980
[TBL] [Abstract][Full Text] [Related]
16. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Pacher P; Szabó C
Cardiovasc Drug Rev; 2007; 25(3):235-60. PubMed ID: 17919258
[TBL] [Abstract][Full Text] [Related]
17. Poly (ADP-ribose) polymerase-1 (PARP-1) as immune regulator.
Laudisi F; Sambucci M; Pioli C
Endocr Metab Immune Disord Drug Targets; 2011 Dec; 11(4):326-33. PubMed ID: 21476963
[TBL] [Abstract][Full Text] [Related]
18. [Poly(ADP-ribose) polymerase (PARP): physiological and pathological roles].
Makogon NV; Aleksieieva IM
Fiziol Zh (1994); 2012; 58(3):95-112. PubMed ID: 22946318
[TBL] [Abstract][Full Text] [Related]
19. Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.
Kauppinen TM
Neurochem Int; 2007 Jun; 50(7-8):954-8. PubMed ID: 17222947
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage.
Moroni F
Curr Opin Pharmacol; 2008 Feb; 8(1):96-103. PubMed ID: 18032109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
